Genomics BioSci & Tech.Ltd Balance Sheet Health
Financial Health criteria checks 4/6
Genomics BioSci & Tech.Ltd has a total shareholder equity of NT$799.3M and total debt of NT$374.0M, which brings its debt-to-equity ratio to 46.8%. Its total assets and total liabilities are NT$1.3B and NT$479.4M respectively.
Key information
46.8%
Debt to equity ratio
NT$374.00m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$261.42m |
| Equity | NT$799.35m |
| Total liabilities | NT$479.36m |
| Total assets | NT$1.28b |
Recent financial health updates
No updates
Recent updates
Is Genomics BioSci & Tech. Co.,Ltd.'s (GTSM:4195) 7.2% Dividend Worth Your Time?
Apr 27
Key Things To Consider Before Buying Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) For Its Dividend
Jan 19
Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Nov 25Financial Position Analysis
Short Term Liabilities: 4195's short term assets (NT$496.8M) exceed its short term liabilities (NT$161.0M).
Long Term Liabilities: 4195's short term assets (NT$496.8M) exceed its long term liabilities (NT$318.4M).
Debt to Equity History and Analysis
Debt Level: 4195's net debt to equity ratio (14.1%) is considered satisfactory.
Reducing Debt: 4195's debt to equity ratio has increased from 8.3% to 46.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4195 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 4195 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 46.5% each year.